William Blair Reiterates Market Perform Rating on uniQure BV (QURE)

William Blair analyst Sami Corwin reiterated a Market Perform rating on uniQure BV (NASDAQ: QURE).

The analyst comments "Stock thoughts: The next 30 days will be critical for uniQure as the pre-BLA meeting minutes will help define the path forward for AMT-130. Given the impressive clinical data shared last month and early patient and physician enthusiasm for AMT-130, it is possible that patient advocacy groups and medical community could put pressure on the agency to negotiate a timely path to BLA submission. In addition, we recognize the company has about $700 million in cash, which will likely be sufficient to fund the company through this turbulent period. However, given that the path forward for AMT-130 is uncertain, with no clear timing for a BLA or other regulatory submission, we reiterate our Market Perform rating."

For an analyst ratings summary and ratings history on uniQure BV click here. For more ratings news on uniQure BV click here.

Shares of uniQure BV closed at $26.15 yesterday.

You May Also Be Interested In

• SpaceX (SPCX) gains nearly 6% as traders follow the money
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• William Blair Downgrades Enovix Corporation (ENVX) to Market Perform